Imatinib Teva Pharma

Imatinib, the active ingredient in Imatinib Teva Pharma, is a tyrosine kinase inhibitor presented as an oral formulation for oral use. It treats chronic myeloid leukemia, gastrointestinal stromal tumor, and Philadelphia chromosome‑positive acute lymphoblastic leukemia in adult patients.

GNH USA supplies Imatinib Teva Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, with established logistics for regulated markets and compliance with EU quality standards. The company provides technical support and documentation to facilitate safe import and clinical use.

Imatinib is a targeted antineoplastic agent that inhibits specific tyrosine kinases involved in certain cancers. - Chronic myeloid leukemia: suppresses BCR‑ABL–driven leukemic cell growth, improving hematologic and cytogenetic response. - Gastrointestinal stromal tumor: blocks c‑KIT signaling, leading to tumor shrinkage and disease control. - Philadelphia chromosome‑positive acute lymphoblastic leukemia: interferes with BCR‑ABL activity, contributing to remission induction.

Imatinib may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Nausea: mild to moderate upset stomach, often transient. - Edema: swelling of hands, feet, or face from fluid retention. - Fatigue: generalized tiredness that may affect daily activities. - Diarrhea: loose stools, sometimes with abdominal cramping. - Muscle cramps: intermittent painful contractions, commonly in limbs. - Rash: skin irritation or redness, occasionally itchy.

Serious or Rare Side Effects: - Hepatotoxicity: significant elevation of liver enzymes or liver injury. - Cardiotoxicity: congestive heart failure or reduced left‑ventricular function. - Severe neutropenia: marked drop in white blood cells, raising infection risk. - Pulmonary hypertension: increased pressure in lung arteries causing breathlessness.

When prescribing Imatinib, several precautions should be observed to ensure patient safety. - Baseline assessment: obtain complete blood count, liver function tests, and cardiac evaluation before initiating therapy. - Monitoring: perform regular CBC, liver enzymes, and renal function during treatment. - Drug interactions: review concomitant medications for CYP3A4 inhibitors or inducers. - Pregnancy and lactation: avoid use unless benefits outweigh potential risks; discuss with specialist. - Patient counseling: advise on reporting signs of infection, swelling, or liver problems promptly. - Store at ambient temperature: keep below 25 °C in original container, protect from moisture and light.

Imatinib interacts with several medicines; awareness of major and moderate interactions helps prevent adverse outcomes.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase Imatinib plasma levels, raising toxicity risk. - Strong CYP3A4 inducers (e.g., rifampicin, phenytoin): may reduce drug exposure, compromising efficacy. - Antacids containing aluminum or magnesium: can decrease absorption if taken simultaneously.

Moderate Interactions (Monitor Closely): - Acid‑reducing agents (e.g., proton pump inhibitors): may modestly lower bioavailability; monitor therapeutic response. - Concomitant anticoagulants (e.g., warfarin): may enhance bleeding risk; check coagulation parameters. - Vaccines (live attenuated): potential reduced efficacy; consider timing relative to therapy.